Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2016-05-23
- Target Recruit Count
- 20
- Registration Number
- NCT02780778
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2016-05-20
- Target Recruit Count
- 40
- Registration Number
- NCT02776527
- Locations
- 🇨🇳
Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2016-05-17
- Target Recruit Count
- 20
- Registration Number
- NCT02774200
PERCIST Criteria for Response Evaluation With Solid Tumors
- Conditions
- Breast NeoplasmsColonic NeoplasmsLymphomaLung Neoplasms
- Interventions
- Other: drug&radiation
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2016-05-06
- Target Recruit Count
- 150
- Registration Number
- NCT02765620
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2017-02-07
- Target Recruit Count
- 30
- Registration Number
- NCT02762474
- Locations
- 🇨🇳
Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia
Phase 2
Completed
- Conditions
- Intranasal Dexmedetomidine Breast Cancer Local Anaesthesia
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2016-03-01
- Target Recruit Count
- 100
- Registration Number
- NCT02675049
Metformin Plus Sorafenib for Advanced HCC
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2016-02-03
- Target Recruit Count
- 82
- Registration Number
- NCT02672488
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer
Not Applicable
- Conditions
- Stage IV Prostate Cancer
- Interventions
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2017-06-12
- Target Recruit Count
- 120
- Registration Number
- NCT02615223
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer
Not Applicable
- Conditions
- Stage III Prostate Cancer
- Interventions
- Procedure: Cryoablation therapyRadiation: External beam radiation therapyDrug: luteinizing-hormone releasing-hormone (LHRH) agonist
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2017-06-12
- Target Recruit Count
- 240
- Registration Number
- NCT02605226
- Locations
- 🇨🇳
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer
Recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2015-07-23
- Target Recruit Count
- 800
- Registration Number
- NCT02506361
- Locations
- 🇨🇳
Jin Zhang, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath